RxDoctor Payments Data

Brittney Edge

Nurse Practitioner · Dothan, ALNPI 1558871830

Payments from drug & device makers

$3,737in general payments, 2019–2025

Across 220 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$656
  • Novartis$403
  • AstraZeneca$349
  • Pfizer$337
  • Philips North America LLC$268
  • Boehringer Ingelheim$254
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,71899%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,737 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$87,235
Medicare patients
584
Services billed
989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$288,066
EntrestoSacubitril/Valsartan88$98,660
XareltoRivaroxaban70$73,392
FarxigaDapagliflozin Propanediol33$30,046
Repatha SureclickEvolocumab33$20,137
BrilintaTicagrelor28$16,121
Ranolazine ErRanolazine111$12,864
Bisoprolol Fumarate261$8,140
ClopidogrelClopidogrel Bisulfate179$2,162
Flecainide Acetate32$1,760
Atorvastatin Calcium156$1,706
Metoprolol Succinate63$1,651
Isosorbide Mononitrate ErIsosorbide Mononitrate149$1,631
Nebivolol Hcl16$1,336
Bumetanide49$1,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$337$288,066295 claims
NovartisEntresto$403$98,66088 claims
Johnson & JohnsonXarelto$83$73,39270 claims
AstraZenecaFarxiga, Brilinta$349$46,16761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →